After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...

After Qualcomm’s purchase of Arduino it has left many wondering what market its new Uno Q board is trying to target. Taking the ongoing RAM-pocalypse as inspiration, [Bringus Studios] made a ...

There’s a new “it” bag — but it doesn’t come with a popular label. Dubbed “analog bags,” Gen Z is buying canvas totes and filling them with items to help them reduce their screen time. The term was ...

Basic economy seats come with cheaper fares, but seat selection and baggage is limited and varies between airlines. Many or all of the products on this page are from partners who compensate us when ...

Back in the 1980s, your options for writing your own code and games were rather more limited than today. This also mostly depended on what home computer you could get your hands on, which was a ...

Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.

Is ADC a buy now?

With a single click, unlock detailed, AI-assisted insights pulled from hundreds of financial data points instantly.